Lower Uric Acid Level At the Time of Allogeneic Hematopoietic Cell Transplantation (HCT) Is Protective Against Acute Graft-Vs-Host-Disease  by Yeh, Albert C. et al.
Abstracts / Biol Blood Marrow Transplant 19 (2013) S129eS149 S143represented in the no-GVHD group. As ST2 concentrations
differed between conditioning intensities, we used 3 models
for prediction using the median ST2 concentrations for UM
FIC, UM RIC, and DFCI FIC as cutpoints.
In multivariate analysis including the age, disease status,
donor source, and HLA match, high ST2 predicted the
development of GVHD in UM FIC, and trended toward
signiﬁcance in the DFCI set (Table 1 Top). Patients with high
ST2 at D14 were at increased risk of D180 NRM for all
conditioning intensities, independent of the clinical charac-
teristics (Table 1 Bottom). High ST2 was not associated with
increased risk of relapse mortality 1 year after HSCT.
In conclusion, high ST2 early in HSCT identiﬁes patients at
high risk for acute GVHD and NRM following HSCT. This has
therapeutic consequences including increased monitoring
and potential preemptive interventions.
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Bronchiolitis obliterans syndrome (BOS) after allogeneic
HSCT is associated with high mortality and unknown path-
ogenesis. We present interim results from a prospective
phase II trial evaluating of montelukast for the treatment of
BOS after HSCT and studying BOS biology. Montelukast
interrupts cysteinyl leukotriene activity and may diminish
homing of activated cells to bronchioles and ﬁbrosis. Twenty-
three patients have enrolled with stable or decreasing
immunosuppression for 3 months prior and BOS diagnosed
by modiﬁed NIH criteria; 2 were withdrawn, and 19 have
completed primary endpoint. Participants ranged from 15-72
years, 13/23 female, most had moderate to severe disease
with baseline FEV1 of 46% predicted (24-73), and median
FEV1/VC 0.5 (0.29-0.78). Montelukast was well-tolerated and
no patient required escalation of BOS-directed therapy
during the evaluation period. All patients met criteria for
treatment success (<15% decline in 6 months), with FEV1
either increased 5-13% of predicted (n¼5), stable (n¼7), or
declined 5-13% (n¼6). FEV1 slope of decline was generated
using regression line of FEV1 value vs. days post-HSCT. At 6
months, slope was improved in 9 patients, stable in 9,
declined in 1. Other manifestations of cGVHD showed: 5/8 GI
GVHD improved and 3/8 stable; 5/10 liver cGVHD improved,4/10 stable, 1 worse, using NIH consensus staging. Survival of
the study cohort is 90% (19/21); 2 year survival is 84% (10/12),
twice published data (44%). Bronchoalveolar lavage (BAL)
from in non-infected patients at baseline revealed cysteinyl
leukotriene receptor expression on CD4 and CD8 T cells,
granulocytes, and eosinophils, thereby potentially impli-
cating these populations in BOS biology. While blood
leukotriene receptor expression on CD4 cells was similar to
normal donors, CD4 proportion was signiﬁcantly reduced in
BOS patients (P < 0.01). Other blood receptor levels of these
populations were similar between normal donors and
controls, although CD8 T cells trended toward decreased
receptor expression after treatment at 6 months and
decreased proportion of CD8 T cells at 2 years (p<0.04). B
cells were absent in BAL while present in blood. These data
suggest that: 1) montelukast is a safe and effective therapy
for BOS after allogeneic HSCT; 2) T cells, granulocytes, and
eosinophils (though not B cells) were associated with BOS in
BAL; and 3) cysteinyl leukotrienes may be a point of regu-
lation in the progression of BOS after HSCT.62
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Acute graft-versus-host disease (aGVHD) is primarily a T-
cell mediated process. Uric acid released from dying cells acts
as a danger signal that alerts the immune system to cell
death and promotes cytotoxic T cell responses. Elimination of
uric acid in mouse models reduces this immune response.
We hypothesized that lower serum uric acid levels at the
time of transplant may decrease the incidence of aGVHD.
Through record review, we recorded serum uric acid levels
from day -7 through day +6 from 43 historical control
patients who received myeloablative HCT (MRD, n¼32;
MUD, n¼11) at the Massachusetts General Hospital between
2007 and 2010, these patients received standard allopurinol.
We also obtained uric acid levels from 23 consecutive
patients (19-59 years) with hematologic malignancies in
complete remission (AML, n¼13; ALL, n¼8; MDS, n¼1; MPD,
n¼1) who were treated in a pilot trial using rasburicase as
part of a myeloablative conditioning regimen, followed by
GCSF-mobilized HLA-matched (MRD, n¼18; MUD, n¼5)
peripheral blood HCT. Urate oxidase (Rasburicase) was
administered beginning on the ﬁrst day of conditioning at
a dose of 0.20 mg/kg IV daily for 5 days starting from day -7.
GVHD prophylaxis for all patients consisted of cyclosporine
or tacrolimus/MTX for MRD transplants and tacrolimus/
MTX/ +/-ATG for MUD transplants. Out of the control group,
patients who developed aGVHD (grade 2+) had a similar
mean serum uric acid level over all days (2.82 mg/dl)
compared to patients who did not have aGVHD (2.86 mg/dl,
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of transplant received, however, as MUD transplants showed
a differential expression in serum uric acid levels between
the two groups (2.64mg/dl for aGVHD+ vs. 2.18 for aGVHD-,
P ¼ .047, Figure 1B), while MRD transplants did not show
a difference (2.97mg/dl for aGVHD+ vs. 2.98 for aGVHD-, P ¼
.95, Figure 1C). Patients given rasburicase had a lower serum
uric acid level compared to the control arm (0.213mg/dl vs.
3.04 for d-7 to -2; 1.20mg/dl vs. 2.85 over all days, P < .0001)
as well as signiﬁcantly less aGVHD (rasburicase: 22% vs.
control: 48%, Fisher's exact test, P ¼ .033). Lower serum uric
acid level at the time of transplantation appears to be
protective against the development of aGVHD among
patients receiving matched unrelated donor transplants.
Rasburicase, when administered during the conditioning,
signiﬁcantly lowers the serum uric acid level and appears to
decrease aGVHD.
Figure 1. Mean uric acid levels from day-7 to day+6 between control patients
who developed aGVHD2+ (Red) vs. no aGVHD2+ (Blue).HEMATOPOIESIS/MESENCHYMAL CELLS ORAL
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Introduction: Despite improvements in the last decade in
the ﬁeld of HSCT, acute graft versus host disease (aGVHD)
remains a life-threatening complication of HSCT. In partic-
ular, the outcome of patients with severe steroid-resistant
aGVHD is very poor. Therefore, it remains important to
search for new therapeutic strategies.
Objective: The feasibility of the generation ofMSCs expanded
with platelet lysate (PL) was tested as well as the feasibility
and safety of the application in patients with steroid-refrac-
tory aGVHD. Immunological changes after infusion of MSC
were characterized, in vitro. However, truly active mecha-
nisms in human are poorly understood as well as whether
infusion of MSC selectively impairs GVHD-inducing immune
cells or also anti-virus and anti-leukemia reactive T-cells.Phenotypical and functional changes in immunological cell
types and cytokine levels were investigated.
Method: In an open-label, non-randomized prospective
phase I/II study MSCs from the bone marrow of healthy
volunteers, expanded with PL. Patients with steroid-refrac-
tory aGVHD grade II-IV were treated with PL-MSC. 50
patients were included and received up to 4 infusions.
Response rate, transplantation-related deaths, and other
adverse events were assessed for up to 12 months after
inclusion. In addition, a comprehensive phenotypical and
functional analysis was performed with PBMCs and serum
isolated from all patients before, during, and after infusion of
MSC.
Results: Between 2009-2012, 50 patients were included, 2
dropped out, 5 are so far incompletely documented. Thus 43
were available for analysis, 6 children and 37 adults. Median
age was 51,5 yr (1.3-65.9). Organs involved in aGVHD were
skin (56%), gi-tract (86%) and liver (33%). Overall grade was II
26%, III 65%, and IV 7%. Mean number of infusion were 3 (1-
4). No severe side effects were observed. Median follow-up
was 4 months (0.4-12). Complete overall response was
observed in 56% patients after a median of 53 days (3-116).
The overall survival was signiﬁcantly better in responders
when compared to non-responders (p <0.001). Immuno-
logical monitoring suggests that anti-viral and anti-leukemia
reactive T-cells are well preserved in all patients who
responded to MSC treatment. In addition, we identiﬁed
biomarkers which associate even 2 weeks after MSC infusion
with complete resolution of GVHD.
Conclusion: Generation and infusion of PL-MSCs in steroid-
resistant aGVHD grade II- IV is feasible, safe and is effective.
In addition, also patients who initially responded to PL-MSCs
but develop later a relapse of aGVHD during tapering or
cessation of immunosuppressive drugs become again sensi-
tive to the treatment with steroids. Infusion of MSC did not
impair anti-virus and anti-leukemia reactive T-cells. Identi-
ﬁed biomarkers predict very early a usually late clinical
resolution of GVHD, thus might be useful.HISTOCOMPATIBILITY/ALTERNATIVE STEM CELL SOURCES
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Background: Retrospective studies suggest that double-unit
cord blood (CB) grafts may improve engraftment and protect
against relapse as compared with that observed after single-
unit CB transplantation (CBT). However, whether the
